ArticleOdontology2026
Changes of salivary secretion after pilocarpine administration twice in a mouse model of Sjögren's syndrome.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sjögren's syndrome (SS) is an autoimmune disease characterized by dysfunction of exocrine glands. Pilocarpine is used as a symptomatic treatment for xerostomia, and chronic administration has been shown to increase salivary secretion; however, the underlying molecular mechanisms remain unclear. This study examined the effects of pilocarpine administration twice on salivary gland function in non-obese diabetic (NOD) mice, an animal model of SS. Pilocarpine was administered to 16-week-old NOD and wild-type (ICR) mice once a week for 2 weeks, and saliva was collected. Salivary volume, amylase activity, and the expression of aquaporin-5 (AQP5), connective tissue growth factor (Ctgf), and serum-and glucocorticoid-regulated kinase-1 (Sgk1) were examined. The salivary volume in ICR mice was significantly increased following the second administration, but not in NOD mice. No significant differences were observed in the total salivary amylase activity in either ICR or NOD mice. Western blot analysis demonstrated higher AQP5 expression in the membrane fractions and significantly lower expression in the cytosolic fractions of the submandibular glands following pilocarpine administration twice in both ICR and NOD mice, although the total AQP5 protein expression levels did not differ between the two types of mice. Gene expression analysis showed that Ctgf and Sgk1 were significantly upregulated in ICR mice following pilocarpine administration twice, but not in NOD mice. These findings suggest that the mechanism underlying the enhanced gene expression of Ctgf and Sgk1 following pilocarpine administration twice is impaired in NOD mice and that the expression of these genes may be associated with pilocarpine-induced salivary secretion.
Indexed as
Identifiers
42166028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.